Why the study?
Does pravastatin 40 mg/d reduce stroke events in patients with coronary disease or hypercholesterolemia compared to placebo?
Does pravastatin 40 mg/d reduce stroke events in patients with coronary disease or hypercholesterolemia compared to placebo?
Pravastatin 40 mg/d significantly reduces the risk of total and nonfatal nonhemorrhagic strokes in patients with documented coronary disease.
Answers are grounded in this paper and cite their sources.
Supports pravastatin for stroke prevention in coronary disease; confirms benefit suggested by recent statin trials.
BACKGROUND: Stroke is a leading cause of death and disability. Although clinical trials of the early lipid-lowering therapies did not demonstrate a reduction in the rates of stroke, data from recently completed statin trials strongly suggest benefit. METHODS AND RESULTS: The effect of pravastatin 40 mg/d on stroke events was investigated in a prospectively defined pooled analysis of 3 large, placebo-controlled, randomized trials that included 19 768 patients with 102 559 person-years of follow-up. In all, 598 participants had a stroke during approximately 5 years of follow-up. The 2 secondary prevention trials (CARE [Cholesterol And Recurrent Events] and LIPID [Long-term Intervention with Pravastatin in Ischemic Disease]) individually demonstrated reductions in nonfatal and total stroke rates. When the 13 173 patients from CARE and LIPID were combined, there was a 22% reduction in total strokes (95% CI 7% to 35%, P:=0.01) and a 25% reduction in nonfatal stroke (95% CI 10% to 38%). The beneficial effect of pravastatin on total stroke was observed across a wide range of patient characteristics. WOSCOPS (West of Scotland Coronary Prevention Study, a primary prevention trial in hypercholesterolemic men) exhibited a similar, although smaller, trend for a reduction in total stroke. Among the CARE/LIPID participants, pravastatin was associated with a 23% reduction in nonhemorrhagic strokes (95% CI 6% to 37%), but there was no statistical treatment group difference in hemorrhagic or unknown type. CONCLUSIONS: Pravastatin reduced the risk of stroke over a wide range of lipid values among patients with documented coronary disease. This effect was due to a reduction in nonfatal nonhemorrhagic strokes.
No takes yet. Share an insight, caveat, or question.
Byington et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: